Zai Lab Ltd

ZLAB

Held by 2 specialist biotech funds

Share on X

Fund Holdings

RTW Investments Rock Springs Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

RTW InvestmentsNEWFeb 17, 2026

Shares: 6,959,032Value: $122.8M

# Signal Note: RTW Investments Initiates $122.8M Position in Zai Lab RTW's substantial entry into ZLAB signals conviction in the company's late-stage oncology pipeline, likely driven by near-term catalysts in its lead assets (zanidatamab for HER2+ gastric cancer, paxalisib in brain tumors). The $122.8M position size—notable for a data-focused investor—suggests confidence in upcoming trial readouts or regulatory milestones that could drive near-term value inflection.

Rock Springs CapitalNEWFeb 17, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX2 funds OMDA2 funds NGNE2 funds PEN2 funds ACAD2 funds ALKS2 funds PTCT2 funds COGT

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# ZLAB Signal Note Rock Springs' $14.3M initiation suggests conviction in ZLAB's clinical catalysts, likely centered on its Phase 3 programs in oncology (zejula in ovarian cancer) and potentially the commercial trajectory of approved assets like danucerone in China. The ~0.8M share position size indicates meaningful but not outsized conviction, consistent with a specialist healthcare manager's typical conviction sizing, warranting monitoring of upcoming trial readouts and China revenue guidance.